WS Investor
10 Feb 2026, 18:23
AstraZeneca reported strong full-year and fourth-quarter 2025 results, supported by broad-based commercial growth and robust pipeline progress. FY 2025 total revenue rose 8% at constant exchange rates to $58.7 billion, driven by Oncology, CVRM, Respiratory & Immunology, and Rare Disease, with growth across all major regions. Core operating profit increased 9%, while core EPS climbed 11% to $9.16. Reported EPS rose 45% to $6.60.
In Q4 2025, total revenue increased 2% at constant exchange rates to $15.5 billion, with product sales up 7%. Reported EPS grew 47% to $1.50, while core EPS was broadly flat at $2.12. The company declared a second interim dividend of $2.17 per share, bringing the full-year dividend to $3.20, up 3% year on year.
During the past twelve months, AstraZeneca delivered 16 positive Phase 3 readouts and secured 43 approvals in major regions, bringing its total to 16 blockbuster medicines. CEO Pascal Soriot said momentum is continuing into 2026, with more than 20 Phase 3 readouts expected this year and over 100 Phase 3 trials ongoing, including a growing number using transformative technologies.
Separately, AstraZeneca’s ordinary shares began trading on the New York Stock Exchange on February 2, creating a harmonised listing across London, New York and Stockholm.
In Q4 2025, total revenue increased 2% at constant exchange rates to $15.5 billion, with product sales up 7%. Reported EPS grew 47% to $1.50, while core EPS was broadly flat at $2.12. The company declared a second interim dividend of $2.17 per share, bringing the full-year dividend to $3.20, up 3% year on year.
During the past twelve months, AstraZeneca delivered 16 positive Phase 3 readouts and secured 43 approvals in major regions, bringing its total to 16 blockbuster medicines. CEO Pascal Soriot said momentum is continuing into 2026, with more than 20 Phase 3 readouts expected this year and over 100 Phase 3 trials ongoing, including a growing number using transformative technologies.
Separately, AstraZeneca’s ordinary shares began trading on the New York Stock Exchange on February 2, creating a harmonised listing across London, New York and Stockholm.